Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial

Basit Öğe Kaydı
dc.contributor.authorDemir, Atakan
dc.contributor.authorMandel, Nil Molinas
dc.contributor.authorPaydas, Semra
dc.contributor.authorDemir, Gökhan
dc.contributor.authorEr, Özlem
dc.contributor.authorTurhal, Nazım Serdal
dc.contributor.authorBavbek, Sevil
dc.contributor.authorEralp, Yeşim
dc.contributor.authorSaip, Pınar Mualla
dc.contributor.authorGüler, Emine Nilüfer
dc.contributor.authorAydıner, Adnan
dc.contributor.authorUluç, Başak Oyan
dc.contributor.authorKılıçkap, Sadettin
dc.contributor.authorÜskent, Necdet
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorYanmaz, Mustafa Teoman
dc.contributor.authorDemir, Hacer
dc.contributor.authorAlan, Özkan
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorOlgun, Polat
dc.contributor.authorUysal, Özlem Sönmez
dc.contributor.authorAltundağ, Kadri
dc.contributor.authorGündüz, Seyda
dc.contributor.authorGünaldı, Meral
dc.contributor.authorSarı, Murat
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorBaşaran, Gül
dc.date.accessioned2021-09-20T11:16:21Z
dc.date.available2021-09-20T11:16:21Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.descriptionWOS:000518031100008
dc.descriptionPMID: 31970972
dc.description.abstractBackground: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2- metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2- patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.en_US
dc.identifier.citationDemir, A., Mandel, N.M., Paydas, S., Demir, G., Er, Ö., Turhal, N.S. ve diğerleri. (2020). Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial. Balkan Medical Journal, 37(2), 104-107.en_US
dc.identifier.endpage107en_US
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue2en_US
dc.identifier.pmid31970972
dc.identifier.startpage104en_US
dc.identifier.urihttps://balkanmedicaljournal.org/en/efficacy-of-palbociclib-and-endocrine-treatment-in-heavily-pretreated-hormone-receptor-positive-her2-negative-advanced-breast-cancer-retrospective-multicenter-trial-161246
dc.identifier.urihttps://hdl.handle.net/11468/7721
dc.identifier.volume37en_US
dc.identifier.wosWOS:000518031100008
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorKaplan, Mehmet Ali
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofBalkan Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectCDK4/6 inhibitorsen_US
dc.subjectPalbocicliben_US
dc.titleEfficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trialen_US
dc.titleEfficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone.pdf
Boyut:
459.78 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu